Molecular mechanism of imatinib-induced thrombocytopenia in treatment of patients with CML.
- Author:
Ling-Ling SHU
1
;
Qian-Li JIANG
;
Fan-Yi MENG
;
Mo YANG
Author Information
1. Department of Hematology, Southern Medical University, Guangdong Province, China.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents;
adverse effects;
therapeutic use;
Benzamides;
Caspase 3;
metabolism;
Humans;
Imatinib Mesylate;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive;
drug therapy;
genetics;
metabolism;
Piperazines;
adverse effects;
therapeutic use;
Platelet-Derived Growth Factor;
metabolism;
Proto-Oncogene Proteins c-akt;
metabolism;
Pyrimidines;
adverse effects;
therapeutic use;
Signal Transduction;
Thrombocytopenia;
chemically induced;
Thrombopoiesis
- From:
Journal of Experimental Hematology
2011;19(5):1314-1318
- CountryChina
- Language:Chinese
-
Abstract:
Imatinib mesylate has been commonly used in the treatment of patients with chronic myeloid leukemia (CML). However, a significant number of CML patients treated with imatinib developed thrombocytopenia. Platelet-derived growth factor (PDGF)/platelet-derived growth factor receptor (PDGFR) plays a significant role in the regulation of thrombopoiesis. It is suggested that imatinib may block the PDGF/PDGFR and PI3-K/Akt pathway, then inducing the apoptosis of megakaryocytes and developing thrombocytopenia in these patients. In this review, the potential molecular mechanism of imatinib-induced thrombocytopenia in the treatment of CML patients is discussed, including imatinib and thrombocytopenia, PDGF/PDGFR and thrombopoiesis, potential mechanism of imatinib-induced thrombocytopenia in treatment of patients with CML and so on.
